在慢性TBI中增强认知功能:α7尼古丁乙胆受体调节的作用
Dinesh K Sangadi1, Akhila Sangadi1, Fabiola Placeres-Uray1
1The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, 1095 NW 14th Terrace, Miami, FL 33136, USA.
Experimental neurology
|December 9, 2023
概括
创伤性脑损伤 (TBI) 会影响学习和记忆. 在TBI后的野生型小鼠中,AVL-3288改善了认知能力,但不是在淘汰的小鼠中,证实alpha7尼古丁乙胆受体 (nAChR) 是关键.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 创伤性脑损伤 (TBI) 导致海马损伤,影响学习和记忆.
- 阿尔法7尼古丁性乙胆受体 (nAChR) 在记忆形成中发挥作用,是TBI的潜在治疗标.
- 以前的研究表明,AVL-3288,一种nAChR调节器,在TBI后的老鼠中改善了认知恢复.
研究的目的:
- 为了确定AVL-3288在TBI后的认知益处是否由alpha7 nAChR特别调解.
- 调查TBI对海马内胆固醇标记物的慢性影响以及AVL-3288治疗的影响.
主要方法:
- 使用Chrna7淘汰赛小鼠和野生类型的 littermates 接受受控皮质冲击 (CCI) 或假手术.
- 在TBI后3个月使用上下文恐惧调节评估认知恢复.
- 在测试和测量海马神经化学标记之前给药AVL-3288或载体.
主要成果:
- 脑损伤显著降低了海马体α7 nAChR,ChAT,ChT和VAChT的表达.
- 在TBI后的野生型小鼠中,AVL-3288治疗改善了学习和记忆.
- 在接受AVL-3288治疗的Chrna7淘汰赛小鼠中没有观察到认知改善,这表明对alpha7 nAChR的依赖.
结论:
- 在TBI恢复的慢性阶段,AVL-3288可以增强认知功能.
- AVL-3288的治疗效果是通过alpha7 nAChR进行的.
- AVL-3288不能逆转TBI诱导的缩,但通过nAChR调制改善认知缺陷.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
01:23Role of Neurotransmitters in Memory
571
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
571
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K